Incyte Corporation (INCY): Will The Stock Price Recover?

3:19 pm ET, 06 Apr 2018

Incyte Corporation (NASDAQ: INCY) was down by more than 19% earlier in today's trading.  What is the stock price forecast (prediction)?

The stock drop occurred after an external data monitoring committee (eDMC) declared a mismatch between the phase 3 study and the primary endpoint of progression-free survival development. The phase 3 study involved evaluation of Incyte's Epacadostat with Merck's Keytruda in metastatic melanoma patients.

Studies indicate that, in combination with certain inhibitors (such as ipilimumab or nivolumab), Epacadostat can cause enhanced cancer therapy response rates, compared to its combination with immune checkpoint inhibitors.

According to Incyte, the survival rate post-therapy shows no statistical significance. So, the company opted to stop further studies after getting the recommendation from eDMC.

Incyte has lost over 16% in the last 3 months. The company claims to keep up its dedication towards the transformation of cancer treatment. It intends to proceed with exploring mechanisms to enhance the outcomes in cancer patients such as IDO1 inhibition.

Will this stock recover? Per Finstead research, Incyte’s average price target is almost $142. The upside looks reasonably high.

Incyte has the highest valuation among its peers. The forward P/E ratio is very high because the company earnings are still rather slim.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finny Bites, please send us an email at hi@askfinny.com.

Top 6 Biotech Stocks For Traders

1:48 am ET, 08 Jan 2018

biotech

Biotech stocks are a risky business—certainly not suitable for retirement investing.  If you’re up for some speculative biotech trades, we are presenting the top 6 among our freshest picks of biotech stocks for the coming 12 months. 

Incyte (INCY)

Now is a good entry point for this drugs development and sales firm. Stocks recently hit a 52-week low. The pipeline of products includes profitable Jakafi for treating bone marrow disorder. 

Alexion Pharmaceuticals (ALXN)

A global biotech firm with a strong balance sheet and new drugs in development. Specializes in life-changing therapies for patients affected by rare diseases. 

Celgene Corporation (CELG)

A stable company showing steady growth in revenue in recent quarters in this high-risk sector. Celgene specializes in cancer and inflammatory diseases, developing its own drugs and collaborating with other large drug producers. Good investing opportunity thanks to a sharp stock decline of over 30% in October 2017. 

Gilead Sciences, Inc. (GILD)

Gilead is a leader in HIV treatment, with a successful hepatitis C product, and is growing steadily around 30% in the last five years. Revenues and operating profit have both increased over 4 years. 

Enzo Biochem, Inc. (ENZ)

Enzo offers a range of therapies that include cardiovascular and infectious diseases plus diabetes and cancer. Its stocks have been on an upward trend since March 2016, forming several new bases since then. 

Vertex Pharmaceuticals (VRTX)

Vertex focuses on cystic fibrosis treatments, and its growth prospects lie in its pipeline. Analysts are excited about its growth prospects, with predictions way ahead of other biotech firms. Vertex has the potential to grow its earnings by 65% annually in the next few years. 

Over the last year, INCY returned -4.90%. This return is lower than Biotechnology sector (78.04%), Healthcare industry (50.71%), and S&P 500 (20.90%) returns.

Over the last year, ALXN returned -11.93%. This return is lower than Biotechnology sector (78.04%), Healthcare industry (50.71%), and S&P 500 (20.90%) returns.

Over the last year, CELG returned -11.70%. This return is lower than Biotechnology sector (78.04%), Healthcare industry (50.71%), and S&P 500 (20.90%) returns.

Over the last year, GILD returned -2.28%. This return is lower than Biotechnology sector (78.04%), Healthcare industry (50.71%), and S&P 500 (20.90%) returns.

Over the last year, ENZ returned +18.10%. This return is lower than Medical Laboratories & Research sector (22.24%), Healthcare industry (46.89%), and S&P 500 (20.90%) returns.

Over the last year, VRTX returned +96.93%. This return is higher than Biotechnology sector (78.04%), Healthcare industry (50.71%), and S&P 500 (20.90%) returns.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finny Bites, please send us an email at hi@askfinny.com.

Incyte Corporation (INCY) Stock Guide

Updated at: 9:58 am ET, 12 Jul 2020

Before we start: if you're looking for INCY stock price, you can quickly find it out by visiting Finny and typing "INCY quote". If you're looking for a quick scoop on INCY stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "INCY". You'll get all this info in one place. Or you can just type "INCY news" to get the latest stock news.

Looking to buy or sell Incyte Corporation (INCY)? Interested in getting the full scoop on INCY, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this INCY stock guide, we'll address key questions about INCY, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are INCY earnings?
2. When is INCY earnings date?
3. What is INCY stock forecast (i.e., prediction)?
4. INCY buy or sell? What is INCY Finny Score?
5. What are the reasons to buy INCY? Why should I buy INCY stock?
6. What are the reasons to sell INCY? Why should I sell INCY stock?
7. What are INCY key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are INCY earnings?

INCY trailing 12-month earnings per share (EPS) is -$1.75.

2. When is INCY earnings date?

INCY earnings date is July 28, 2020.

Analyst Predictions

3. What is INCY stock forecast (i.e., prediction)?

Based on INCY analyst price targets, INCY stock forecast is $95.33 (for a year from now). That means the average analyst price target for INCY stock is $95.33. The prediction is based on 21 analyst estimates.

The low price target for INCY is $74.00, while the high price target is $122.00.

INCY analyst rating is Buy.

Analysis

4. INCY buy or sell? What is INCY Finny Score?

#{finnyScore:50}Our quantitative analysis shows 5 reasons to buy and 5 reasons to sell INCY, resulting in Finny Score of 50.

5. What are the reasons to buy INCY? Why should I buy INCY stock?

Here are the reasons to buy INCY stock:

  • Incyte's Jakafi is the first and only FDA-approved treatment for a rare blood disorder known as myelofibrosis, giving it strong pricing power and market penetration.
  • Xeljanz's delayed European entry and AstraZeneca's abandonment of fostamatinib open the door for Incyte's baricitinib to be a leading oral treatment for rheumatoid arthritis in the near term.
  • Incyte's selective IDO1 inhibitor program is a leading next-generation immuno-oncology asset.
  • INCY quarterly revenue growth was 14.20%, higher than the industry and sector average revenue growth (0.52% and 1.16%, respectively). See INCY revenue growth chart.
  • INCY profitability is improving. The YoY profit margin change was 26.20 percentage points. See INCY profitability chart.
  • INCY PEG ratio (P/E adjusted for growth) is 1.00, which is low compared to its industry peers’ PEG ratios. See INCY PEG chart.
  • INCY average analyst rating is Buy. See INCY analyst rating chart.
  • INCY cash to debt ratio is 18.20, higher than the average industry (0.16) and sector (0.16) cash to debt ratio. See INCY cash to debt chart.

6. What are the reasons to sell INCY? Why should I sell INCY stock?

Let's look at the reasons to sell INCY stock (i.e., the bear case):

  • Though early-stage, pipeline competition could reach the market and upend Incyte's monopoly on the myelofibrosis market.
  • Oral rheumatoid arthritis candidate baricitinib faces a crowded market.
  • Incyte has been reinvesting all profits from Jakafi in its highly uncertain pipeline.
  • INCY stock price ($104.76) is close to the 52-week high ($109.16). Perhaps now is a good time to sell? See INCY price chart.
  • INCY forward P/E ratio is 23.59, which is high compared to its industry peers’ P/E ratios. See INCY forward P/E ratio chart.
  • INCY Price/Book ratio is 10.62, which is high compared to its industry peers’ P/B ratios. See INCY forward Price/Book ratio chart.
  • INCY average analyst price target ($95.33) is below its current price ($104.76). See INCY price target chart.
  • INCY short interest (days to cover the shorts) ratio is 3.03. The stock garners more short interest than the average industry, sector or S&P 500 stock. See INCY short interest ratio chart.

Key Stats

7. What are INCY key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for INCY:

Metrics INCY
Price $93.58
Average Price Target / Upside $95.33 / 1.87%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 1,367
Market Cap $21.2B
Forward P/E Ratio 25.31
Price/Book Ratio 8.88
Revenue (TTM) $2.39B
YoY Quarterly Revenue Growth 29.80%
Profit Margin -8.00%

If you liked this analysis, check out Stock Guides for other stocks.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finny Bites, please send us an email at hi@askfinny.com.

Use Finny to ask any finance or investment question. Big or small. Personal or general.
Follow Us